Ipilimumab, which is the first FDA-approved ICI, and tremelimumab (CTLA-4 inhibiting agents) are usually prescribed for melanomas, renal cell carcinomas (RCC), non-small cell lung cancer (NSCLC), pleural mesotheliomas, and hepatocellular carcinomas (HCC). This evidence concerns the gene CTLA4 and renal cell carcinoma.